NASDAQ: PMN - ProMIS Neurosciences, Inc.

Yield per half year: -47.74%
Sector: Healthcare

Share chart ProMIS Neurosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

More details
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

ISIN CA74346M4065
Цена ао 1.94
Выручка 0
EBITDA -0.0044
Число акций ао 0.01229 млрд
P/S 56837.14
P/BV 171.6
EV/EBITDA -9.02
Сайт https://www.promisneurosciences.com
Валюта usd
IPO date 2007-07-17
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: -0.0392% (1.0194)
Change price per week: -1.07% (1.03)
Change price per month: -17.15% (1.23)
Change price per 3 month: -51.29% (2.092)
Change price per half year: -47.74% (1.95)
Change price per year: -44.32% (1.83)
Change price per 3 year: +579.33% (0.15)
Change price per 5 year: +466.11% (0.18)
Change price per year to date: -27.21% (1.4)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2.24 7
P/E 0 0
EV/EBITDA 0.2826 10
Total: 4.63

Efficiency

Title Value Grade
ROA, % -73.22 0
ROE, % -265.68 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 150.22 10
Yield EPS, % -17.95 0
Total: 6
More

Institutions Volume Share, %
Sphera Funds Management Ltd. 1834042 9.67
Ally Bridge Group (NY) LLC 1066674 5.63
Affinity Asset Advisors, LLC 265958 1.4
Northeast Financial Consultants Inc 100000 0.53
IEQ CAPITAL, LLC 30799 0.16
Fiduciary Trust Company (MA) 20008 0.11
Kingsview Wealth Management, LLC 11100 0.06
Claret Asset Management Corp 10830 0.06
UBS Group AG 5926 0.03
Bank of America Corporation 1666 0.01



Head Job title Payment Year of birth
Dr. Neil R. Cashman M.D. Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director 333.8k 1952 (72 years)
Mr. Gavin T. Malenfant Chief Operating Officer 413.49k 1964 (60 years)
Mr. Daniel E. Geffken M.B.A. Chief Financial Officer 89.99k 1957 (67 years)
Dr. Johanne Kaplan Ph.D. Chief Development Officer 263.07k 1960 (64 years)
Dr. Ernest D. Bush Ph.D. Head of Pharmacology/Toxicology & Senior Consultant N/A
Dr. David Wishart Ph.D. Chief Physics Officer N/A
Mr. Dennis Chen Ph.D. Head of Manufacturing & Senior Consultant N/A
Dr. Larry Douglas Altstiel M.D., Ph.D. Chief Medical Officer N/A 1950 (74 years)
Mr. Neil K. Warma M.B.A. President, Interim CEO & Director 40k 1963 (61 year)
Mr. Eugene W. Williams Co-Founder & Chairman 1959 (65 years)

Address: Canada, Toronto. ON MS E, 1920 Yonge Street - open in Google maps, open in Yandex maps
Website: https://www.promisneurosciences.com